Anadys begins dosing in ANA598 Phase IIb research for hepatitis C Anadys Pharmaceuticals, Inc. Announced today that dosing has begun in the Phase IIb research of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C individuals prednisonetablets.com/prednisone-vs.-prednisolone . The Company expects to receive Week 8 antiviral response data for treatment-naive sufferers by the finish of the second quarter of 2011, Week 12 antiviral response data for treatment-experienced sufferers in the third one fourth of 2011 and Week 24 antiviral response data for both groupings in the fourth quarter of 2011.